Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's stock (REGN) has experienced fluctuations in the past six months. As of October 3, 2025, the share price was $600.00, a 39.76% decline from October 7, 2024. Over the past year, the stock is down over 40%. However, more recently, the stock has shown some positive movement, with a 6.76% rise compared to the previous week and a 3.09% rise over the last month as of September 27, 2025. Key events impacting the stock include the Q1 2025 and Q2 2025 earnings releases, the Annual General Meeting, the approval of Evkeeza, a positive CHMP opinion for Dupixent, positive results from late-stage trials, and the upcoming Q3 2025 earnings report.

Information directly detailing the demand seasonality for Regeneron Pharmaceuticals, Inc.'s products and services was not explicitly found in the provided search results. The available data primarily discusses tools and analyses for identifying seasonality in REGN's stock price movements, rather than the underlying demand for its pharmaceutical products. Pharmaceutical product demand can be influenced by various factors, including disease prevalence, treatment cycles, and new drug approvals, but specific seasonal patterns for Regeneron's product demand are not detailed.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases, operating within the biotechnology and pharmaceutical sectors. Regeneron develops products for conditions including allergic and inflammatory diseases, eye diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, hematologic conditions, and rare diseases, utilizing technologies like VelociSuite. The company partners with firms like Sanofi and Bayer for product development and commercialization. Key products include Eylea for ophthalmic conditions, Dupixent for atopic dermatitis and other conditions, Libtayo for certain cancers, Praluent to reduce cardiovascular event risk, Evkeeza for a rare form of high cholesterol, Inmazeb for Ebola, Arcalyst for autoinflammatory conditions, Zaltrap for metastatic colorectal cancer and REGEN-COV for COVID-19.

Regeneron Pharmaceuticals operates globally with its headquarters in Tarrytown, New York. The company operates in the United States and other regions, with offices in 12 countries and clinical trials in over 50 countries. Manufacturing units are located in the U.S. and Ireland. Its products are available in countries including the U.S., the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. International sales have grown substantially from 2022 to 2024, indicating an expanding global market presence.

Regeneron Pharmaceuticals maintains a strong brand reputation as a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines. The company's reputation has been positively influenced by the approval of Evkeeza in the U.S. and the positive EU opinion for Dupixent. Positive results from late-stage clinical trials for obesity and fibrodysplasia ossificans progressiva also contribute to a favorable perception. No specific negative events significantly impacting Regeneron's brand reputation in the past year were identified.

Regeneron Pharmaceuticals has a diverse ownership structure, with approximately 79% to 87.9% of shares owned by institutional investors, 5.42% to 37.95% by insiders, and 6.56% to 23.45% by the general public. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Sanofi is the largest individual shareholder, owning 34.46% of the company, and Leonard Schleifer, CEO and Co-Founder, also holds a significant number of shares.